AKT Inhibition in Prostate Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics:

Tolerability of capivasertib and management of associated side effects — Question from Neeraj Agarwal, MD, FASCO (0:00)
Case: A man in his early 70s with Type 2 diabetes presents with metastatic hormone-sensitive prostate cancer with widespread bone metastases and PTEN deficiency on next-generation sequencing and receives relugolix/darolutamide — Rana R McKay, MD, FASCO (8:39)